Time from stopping blood thinner to bypass surgery may be shortened for select patients

Dr. Derek So presented the late-breaking results of the trial “Reassessment of Anti-Platelet Therapy Using InDividualized Strategies - Ticagrelor in Patients With Acute Coronary Syndromes Treated by Coronary Artery Bypass Graft Surgery (RAPID CABG)” at the American Heart Association’s Scientific Sessions 2021 on November 13.

According to the research, people who are on the antiplatelet medication ticagrelor and need coronary artery bypass surgery may be able to safely have the procedure after waiting less time than typically recommended after the medication is stopped. This may also decrease hospital length of stay.

Read the AHA news release

Media contact

Sitraka Raoelimanohisoa
Coordinator, Communications
University of Ottawa Heart Institute
613-899-6760 (cell)
sraoelimanohisoa@ottawaheart.ca

Share This